Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection

NCT07689578 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Antibody Mediated Rejection After Kidney Transplantation

Interventions

DRUG: BiTE (BCMA x CD3 Bispecific Antibody)

Sponsor

Turun Song